Bristol-Myers: CHMP Recommends Approval Of Opdivo For Two New Indications

(RTTNews) - Bristol-Myers Squibb Company (BMY) announced the Committee for Medicinal Products for Human Use, or CHMP, has recommended the approval of Opdivo (nivolumab) for two new indications - adults with locally advanced or metastatic non-small cell lung cancer after prior chemotherapy, and adults with advanced renal cell carcinoma after prior therapy. The CHMP positive opinions will now be reviewed by the European Commission.

Opdivo is already approved by the European Union for advanced melanoma and previously treated advanced squamous non-small cell lung cancer.